BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23071290)

  • 1. Treatment with medroxyprogesterone acetate plus levonorgestrel-releasing intrauterine system for early-stage endometrial cancer in young women: single-arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2009).
    Kim MK; Seong SJ; Lee TS; Kim JW; Nam BH; Hong SR; Suh KS
    Jpn J Clin Oncol; 2012 Dec; 42(12):1215-8. PubMed ID: 23071290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer.
    Kim MK; Seong SJ; Kim YS; Song T; Kim ML; Yoon BS; Jun HS; Lee YH
    Am J Obstet Gynecol; 2013 Oct; 209(4):358.e1-4. PubMed ID: 23791687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer.
    Kim MK; Seong SJ; Song T; Kim ML; Yoon BS; Jun HS; Lee GH; Lee YH
    Gynecol Oncol; 2013 Sep; 130(3):470-3. PubMed ID: 23822890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of diagnostic accuracy between endometrial curettage and pipelle aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group Study (KGOG 2019).
    Kim MK; Seong SJ; Lee TS; Ki KD; Lim MC; Kim YH; Kim K; Joo WD
    Jpn J Clin Oncol; 2015 Oct; 45(10):980-2. PubMed ID: 26206899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-Oncology Group Study.
    Kim MK; Seong SJ; Kang SB; Bae DS; Kim JW; Nam JH; Lim MC; Lee TS; Kim S; Paek J
    J Gynecol Oncol; 2019 Mar; 30(2):e47. PubMed ID: 30740964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: single arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2006).
    Lee TS; Seong SJ; Kim JW; Ryu HS; Song ES; Nam BH
    Jpn J Clin Oncol; 2011 Jun; 41(6):817-9. PubMed ID: 21478178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system.
    Kim DH; Seong SJ; Kim MK; Bae HS; Kim M; Yun BS; Jung YW; Shim JY
    J Gynecol Oncol; 2017 Jan; 28(1):e1. PubMed ID: 27670255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conservative treatment with medroxyprogesterone acetate plus levonorgestrel intrauterine system for early-stage endometrial cancer in young women: pilot study.
    Kim MK; Yoon BS; Park H; Seong SJ; Chung HH; Kim JW; Kang SB
    Int J Gynecol Cancer; 2011 May; 21(4):673-7. PubMed ID: 21546871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma.
    Giannopoulos T; Butler-Manuel S; Tailor A
    Gynecol Oncol; 2004 Dec; 95(3):762-4. PubMed ID: 15582001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of high-dose progestin and long-term outcomes in young women with early-stage, well-differentiated endometrioid adenocarcinoma of uterine endometrium.
    Park H; Seok JM; Yoon BS; Seong SJ; Kim JY; Shim JY; Park CT
    Arch Gynecol Obstet; 2012 Feb; 285(2):473-8. PubMed ID: 21706284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progestogen treatment options for early endometrial cancer.
    Cade TJ; Quinn MA; Rome RM; Neesham D
    BJOG; 2010 Jun; 117(7):879-84. PubMed ID: 20394609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levonorgestrel-releasing intrauterine system alone as primary treatment in young women with early endometrial cancer: case report.
    Fambrini M; Bargelli G; Peruzzi E; Buccoliero AM; Pieralli A; Andersson KL; Scarselli G; Gallorini M; Zolfanelli F; Marchionni M
    J Minim Invasive Gynecol; 2009; 16(5):630-3. PubMed ID: 19835809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system.
    Kresowik J; Ryan GL; Van Voorhis BJ
    Obstet Gynecol; 2008 Feb; 111(2 Pt 2):547-9. PubMed ID: 18239018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol.
    Zhao X; Niu J; Shi C; Liu Z
    Reprod Health; 2022 Nov; 19(1):206. PubMed ID: 36333773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.
    Zhou H; Cao D; Yang J; Shen K; Lang J
    Int J Gynecol Cancer; 2017 Jul; 27(6):1178-1182. PubMed ID: 28562472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding.
    Crosignani PG; Vercellini P; Mosconi P; Oldani S; Cortesi I; De Giorgi O
    Obstet Gynecol; 1997 Aug; 90(2):257-63. PubMed ID: 9241305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature.
    Dhar KK; NeedhiRajan T; Koslowski M; Woolas RP
    Gynecol Oncol; 2005 Jun; 97(3):924-7. PubMed ID: 15943993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study.
    Pashov AI; Tskhay VB; Ionouchene SV
    Gynecol Endocrinol; 2012 Jul; 28(7):559-61. PubMed ID: 22296608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System: A Korean Gynecologic-Oncology Group Study.
    Kim MK; Seong SJ; Kim JW; Jeon S; Choi HS; Lee IH; Lee JH; Ju W; Song ES; Park H; Ryu HS; Lee C; Kang SB
    Int J Gynecol Cancer; 2016 May; 26(4):711-5. PubMed ID: 26905333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Oral Medroxyprogesterone/Levonorgestrel-Intrauterine System Treatment for Women With Grade 2 Stage IA Endometrial Cancer.
    Hwang JY; Kim DH; Bae HS; Kim ML; Jung YW; Yun BS; Seong SJ; Shin E; Kim MK
    Int J Gynecol Cancer; 2017 May; 27(4):738-742. PubMed ID: 28346240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.